Posted by Michael Wonder on 11 Aug 2022
Amgen's acute lymphoblastic leukaemia drug Blincyto passes reimbursement review
11 August 2022 - Amgen's acute lymphoblastic leukaemia treatment Blincyto (blinatumomab) passed the reimbursement review about two years after expanding indication to treat minimal residual disease in patients with B-cell precursor acute lymphoblastic leukaemia.
In contrast, Amgen's Xgeva (denosumab), which prevents skeletal-related events in cancer patients, failed to pass the reimbursement review by the Health Insurance Review and Assessment Service's cancer drugs benefit appraisal committee.
